Last 29 quarters of trend data · Healthcare · Medical Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.22 | 0.90 | 0.60 | 0.66 | 1.01 | 0.77 | 1.09 | 2.98 | 2.79 | 3.99 | 2.97 | 4.75 | 6.35 | 5.57 | 7.21 | 7.22 | 5.11 | 11.47 | 9.76 | 21.17 | 21.43 |
| — | +17.1% | -44.8% | -78.0% | -63.8% | -80.7% | -63.3% | -37.2% | -56.0% | -28.3% | -58.8% | -34.3% | +24.2% | -51.4% | -26.1% | -65.9% | -76.2% | -53.6% | -70.0% | -51.6% | -64.0% | |
| P/B Ratio | 1.92 | 2.41 | 1.40 | 1.18 | 1.69 | 1.10 | 1.51 | 3.46 | 3.09 | 3.47 | 2.44 | 3.24 | 4.14 | 3.13 | 3.70 | 2.92 | 2.05 | 3.79 | 3.16 | 5.01 | 6.08 |
| — | +118.3% | -7.1% | -65.9% | -45.4% | -68.1% | -38.3% | +6.8% | -25.2% | +10.7% | -34.1% | +11.1% | +102.1% | -17.4% | +17.0% | -41.8% | -66.3% | -41.4% | -58.2% | -32.9% | -41.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 74.2% | 76.2% | 78.0% | 77.9% | 77.6% | 74.7% | 72.1% | 72.5% | 74.0% | 73.7% | 73.7% | 74.1% | 74.2% | 73.7% | 74.1% | 72.9% | 72.5% | 75.2% | 74.7% | 75.2% | 74.8% |
| — | +2.1% | +8.1% | +7.5% | +4.9% | +1.3% | -2.1% | -2.2% | -0.2% | -0.1% | -0.6% | +1.8% | +2.3% | -1.9% | -0.8% | -3.1% | -3.0% | +2.4% | +0.9% | +5.2% | +3.9% | |
| Operating Margin | -59.3% | -32.8% | -39.8% | -62.9% | -43.8% | -66.9% | -62.0% | -64.6% | -56.5% | -69.3% | -75.2% | -77.1% | -72.2% | -85.9% | -95.6% | -112.8% | -94.8% | -103.2% | -103.3% | -145.3% | -90.2% |
| — | +51.0% | +35.9% | +2.6% | +22.4% | +3.4% | +17.5% | +16.2% | +21.8% | +19.3% | +21.4% | +31.7% | +23.9% | +16.7% | +7.4% | +22.3% | -5.1% | -40.2% | +0.6% | -7.5% | +5.2% | |
| Net Margin | -59.7% | -36.8% | -44.3% | -66.3% | -46.1% | -64.9% | -63.6% | -64.1% | -55.4% | -69.4% | -73.7% | -72.9% | -72.0% | -84.3% | -94.2% | -109.1% | -92.6% | -105.0% | -104.9% | -146.8% | -94.9% |
| — | +43.4% | +30.3% | -3.5% | +16.8% | +6.4% | +13.8% | +12.1% | +23.0% | +17.7% | +21.7% | +33.2% | +22.2% | +19.7% | +10.2% | +25.6% | +2.4% | -36.7% | +1.2% | -8.4% | -0.3% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -77.2% | -22.9% | -23.7% | -27.3% | -18.3% | -21.6% | -20.7% | -17.7% | -14.7% | -14.5% | -14.5% | -12.0% | -11.4% | -11.5% | -11.7% | -10.6% | -9.0% | -8.4% | -8.3% | -8.4% | -6.6% |
| — | -5.8% | -14.8% | -54.7% | -24.6% | -49.1% | -42.8% | -47.1% | -28.8% | -26.3% | -24.2% | -12.9% | -26.5% | -35.9% | -41.1% | -26.2% | -37.0% | -71.2% | -36.0% | -49.2% | +19.9% | |
| ROA | -37.0% | -7.5% | -8.6% | -11.0% | -7.8% | -9.8% | -10.2% | -9.2% | -8.0% | -8.3% | -9.1% | -8.0% | -7.7% | -7.9% | -8.2% | -8.0% | -7.2% | -6.8% | -6.7% | -6.9% | -5.4% |
| — | +23.7% | +15.7% | -18.9% | +2.3% | -17.5% | -12.1% | -14.7% | -4.2% | -5.6% | -10.7% | -0.1% | -6.2% | -15.4% | -22.2% | -16.1% | -33.6% | -66.3% | -30.7% | -43.3% | +2.8% | |
| ROIC | -72.0% | -14.5% | -17.0% | -24.0% | -18.4% | -23.9% | -20.1% | -16.6% | -12.7% | -11.7% | -13.4% | -13.9% | -14.0% | -15.4% | -16.2% | -16.0% | -14.4% | -13.0% | -12.5% | -14.7% | -16.5% |
| — | +39.2% | +15.5% | -44.4% | -45.3% | -103.7% | -49.9% | -19.8% | +9.4% | +24.0% | +17.5% | +13.5% | +2.6% | -18.5% | -30.2% | -9.1% | +12.7% | +30.3% | +53.3% | +56.5% | +53.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.04 | 1.65 | 1.43 | 1.23 | 1.04 | 0.94 | 0.82 | 0.73 | 0.66 | 0.60 | 0.56 | 0.37 | 0.35 | 0.34 | 0.32 | 0.30 | 0.16 | 0.15 | 0.20 | 0.20 | 0.14 |
| — | +74.9% | +74.4% | +67.8% | +58.3% | +56.7% | +48.1% | +99.7% | +88.0% | +79.1% | +73.0% | +21.3% | +121.0% | +118.1% | +61.0% | +54.8% | +15.7% | +16.6% | +59.7% | +58.0% | +13.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.07 | 4.05 | 4.32 | 4.91 | 5.07 | 4.86 | 5.35 | 4.97 | 5.58 | 7.70 | 8.97 | 6.95 | 6.50 | 7.19 | 8.42 | 10.62 | 9.14 | 8.44 | 9.43 | 11.33 | 11.85 |
| — | -16.6% | -19.2% | -1.3% | -9.1% | -36.9% | -40.4% | -28.5% | -14.2% | +7.1% | +6.4% | -34.6% | -28.9% | -14.8% | -10.7% | -6.3% | -22.9% | -17.6% | -34.0% | -33.6% | -40.6% | |
| Quick Ratio | 4.28 | 3.31 | 3.52 | 4.04 | 4.28 | 4.15 | 4.63 | 4.29 | 4.88 | 6.77 | 7.92 | 6.14 | 5.77 | 6.41 | 7.62 | 9.70 | 8.35 | 7.73 | 8.49 | 10.30 | 10.92 |
| — | -20.3% | -24.0% | -5.9% | -12.4% | -38.7% | -41.6% | -30.0% | -15.4% | +5.7% | +4.0% | -36.7% | -30.9% | -17.1% | -10.2% | -5.8% | -23.6% | -19.3% | -36.9% | -36.5% | -42.8% | |
| Interest Coverage | -15.92 | -5.68 | -7.17 | -12.84 | -12.30 | -16.18 | -17.77 | -19.33 | -14.60 | -14.66 | -16.11 | -14.36 | -14.07 | -15.62 | -17.58 | -26.56 | -38.10 | -48.55 | -64.47 | -78.60 | -63.59 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 29 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LUNG stock.
Pulmonx Corporation's current P/E is -2.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pulmonx Corporation's current operating margin is -59.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pulmonx Corporation's business trajectory between earnings reports.